- Report
- October 2025
- 168 Pages
Global
From €5189EUR$5,850USD£4,505GBP
- Report
- September 2025
- 82 Pages
Global
From €3500EUR$4,227USD£3,145GBP
- Report
- July 2025
- 112 Pages
Europe
From €5318EUR$5,995USD£4,617GBP
- Report
- July 2025
- 81 Pages
North America
From €5318EUR$5,995USD£4,617GBP
- Report
- June 2025
- 36 Pages
United States
From €4431EUR$4,995USD£3,847GBP
- Report
- June 2025
- 29 Pages
Germany
From €4431EUR$4,995USD£3,847GBP
- Book
- February 2023
North America

Metabolic Syndrome is a cluster of medical conditions that occur together, increasing the risk of heart disease, stroke, and diabetes. It is characterized by a combination of abdominal obesity, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, and low high-density lipoprotein cholesterol. It is a major public health concern due to its high prevalence and associated health risks.
Metabolic Syndrome is a complex disorder with multiple causes, including genetic, environmental, and lifestyle factors. It is associated with an increased risk of cardiovascular disease, type 2 diabetes, and other chronic diseases. Treatment typically involves lifestyle modifications, such as diet and exercise, as well as medications to control blood pressure and cholesterol levels.
Companies in the Metabolic Syndrome market include Novo Nordisk, Sanofi, Merck, and AstraZeneca. Show Less Read more